Skip to content

A human study for investigating effects of Lycium barbarum extract consumption on antioxidative capacity in hypercholesterolemic adults

A human study for investigating effects of Lycium barbarum extract consumption on antioxidative capacity in hypercholesterolemic adults : a randomized, double-blind, placebo-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0000729
Enrollment
54
Registered
2013-04-26
Start date
2013-03-29
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Consumption of placebo or Lycium barbarum extract for 8 weeks

Sponsors

Ewha Womans University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agrees to participate and signs in informed consent form 2) Age: = 30 years 3) BMI: = 23kg/m2 and < 30kg/m2 4) Plasma LDL cholesterol levels = 130mg/dl

Exclusion criteria

Exclusion criteria: 1) Continuous consumption of dietary supplements or medicine which can affect antioxidative capacity within 4 weeks before the first visit 2) Continuous consumption of Lycium barbarum within 4 weeks before the first visit 3) Continuous administration of drugs which can affect antioxidative capacity within 4 weeks before the first visit (hypolipidemic, antiinflammatory drug, hypotensive, antibiotics, aspirin, hypoglycemic, anticoagulant) 4) Subject with following diseases and past medical history within 2 years before the first visit (Hypertension, diabetes, atherosclerosis, chronic inflammatory disease, CVD, renal disease, liver disease, thyroid disease, malignant tumor, mental illness) 5) Subject who loses weight over 4kg within 30 day before the first visit 6) Consumption of alcohol (= 140g/week) 7) Smoker (= 10 cigarettes/day) 8) Excessive exercise (= 7 hours/week) 9) Pregnant women, lactating women, or menopausal women with hormone therapy 10) Participation in other human study within 4 weeks before the first visit 11) Subjects with hypersensitivity to test materials 12) Any condition that the principal investigator believes may put the subjects at undue risk

Design outcomes

Primary

MeasureTime frame
Antioxidative markers

Secondary

MeasureTime frame
Lipid profiles, etc.

Countries

Korea, Republic of

Contacts

Public ContactJieun Park

Ewha Womans University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026